Physician profile
John Porter
NPI 1487636999
$17,497.85
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $2,736 · 2021: $9,261 · 2022: $2,892 · 2023: $1,470 · 2024: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,050 · Food and Beverage: $394 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,050.00 |
| Food and Beverage | $393.99 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,314.57 | 2021-2023 | |
| Allergan, INC. | $4,131.74 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $641.76 | 2019-2023 | |
| Biogen, INC. | $403.26 | 2019-2023 | Tysabri, Vumerity |
| Amneal Pharmaceuticals LLC | $240.92 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $213.33 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $185.26 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $182.25 | 2021 | |
| Chiesi USA, INC. | $124.47 | 2024 | Cleviprex |
| Medtronic, INC. | $124.16 | 2023 | Linq II |
| Emd Serono, INC. | $70.62 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $61.33 | 2019-2021 | |
| Lilly USA, LLC | $59.96 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $58.80 | 2021-2022 | |
| Horizon Therapeutics Plc | $58.48 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $51.82 | 2021-2023 | Andexxa |
| Sk Life Science, INC. | $45.30 | 2021-2023 | |
| Aquestive Therapeutics, INC. | $42.61 | 2020 | |
| Akcea Therapeutics, INC. | $40.53 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $39.38 | 2021 | |
| Alexion Pharmaceuticals, INC. | $33.07 | 2023 | Ultomiris |
| Eisai INC. | $31.69 | 2021-2022 | |
| Genentech USA, INC. | $31.41 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Grifols USA, LLC | $28.99 | 2020-2023 | Gamunex-C |
| Kyowa Kirin, INC. | $27.83 | 2019-2020 | |
| Ucb, INC. | $26.41 | 2019-2022 | |
| Lundbeck LLC | $25.18 | 2019 | |
| Csl Behring | $22.94 | 2021 | |
| Livanova USA, INC. | $22.44 | 2019 | |
| Banner Life Sciences, LLC | $20.24 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.58 | 2022 | |
| Amgen INC. | $19.14 | 2019 | |
| Tanabe Pharma America, INC. | $18.35 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.33 | 2021 | |
| Celgene Corporation | $16.40 | 2021 | |
| Mdd US Operations, LLC | $15.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.